Bioventus Inc. Enters Material Definitive Agreement
Ticker: BVS · Form: 8-K · Filed: Jun 21, 2024 · CIK: 1665988
Sentiment: neutral
Topics: material-agreement, definitive-agreement
Related Tickers: BIOV
TL;DR
Bioventus signed a big deal, details TBD.
AI Summary
Bioventus Inc. announced on June 19, 2024, that it entered into a material definitive agreement. The filing does not disclose specific details of the agreement, the counterparty, or any associated financial figures.
Why It Matters
This filing indicates a significant new development for Bioventus Inc., potentially impacting its business operations, financial standing, or strategic direction.
Risk Assessment
Risk Level: medium — The lack of specific details in the filing creates uncertainty about the nature and implications of the agreement, warranting a medium risk assessment.
Key Players & Entities
- Bioventus Inc. (company) — Registrant
- June 19, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-37844 (identifier) — Commission File Number
- 81-0980861 (identifier) — IRS Employer Identification Number
- 4721 Emperor Boulevard, Suite 100 Durham, North Carolina 27703 (address) — Address of principal executive offices
- (919) 474-6700 (phone_number) — Registrant's telephone number
FAQ
What is the nature of the material definitive agreement entered into by Bioventus Inc.?
The filing does not specify the nature of the material definitive agreement.
Who is the counterparty to this material definitive agreement?
The filing does not disclose the identity of the other party to the agreement.
What is the effective date of this agreement?
The earliest event reported is dated June 19, 2024.
Are there any financial terms or obligations associated with this agreement mentioned in the filing?
No specific financial terms or obligations are detailed in this 8-K filing.
Does this agreement represent a significant change in Bioventus Inc.'s business operations?
The filing indicates a 'material definitive agreement,' suggesting it could be significant, but specific impacts are not detailed.
Filing Stats: 531 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2024-06-21 16:30:55
Key Financial Figures
- $0.001 — which registered Class A common Stock, $0.001 par value per share BVS The Nasdaq
Filing Documents
- d821942d8k.htm (8-K) — 25KB
- d821942dex101.htm (EX-10.1) — 25KB
- 0001193125-24-165735.txt ( ) — 178KB
- bvs-20240619.xsd (EX-101.SCH) — 3KB
- bvs-20240619_lab.xml (EX-101.LAB) — 18KB
- bvs-20240619_pre.xml (EX-101.PRE) — 11KB
- d821942d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Amendment No. 1 to the Stockholders Agreement by and among Bioventus Inc., Bioventus LLC and the Principal Stockholders dated as of June 19, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOVENTUS INC. Date: June 21, 2024 By: /s/ Anthony D'Adamio Anthony D'Adamio Senior Vice President and General Counsel